News | February 25, 2025
Biocon Biologics launches Yesintek Biosimilar to Stelara in US
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
Among those identified, 2.4 lakh patients have been notified from public health institutions, while 1.1 lakh were identified through private healthcare facilities
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
IMCD India’s innovative formulations bring the Skinification trend to life with cutting-edge solutions across beauty and personal care
Theatre (OTs) dedicated to cataract, LASIK, and retina treatments added to meet the growing demand
Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
Subscribe To Our Newsletter & Stay Updated
